Sab Biotherapeutics’ New Study Targets Type 1 Diabetes Progression

Sab Biotherapeutics, Inc. ((SABS)) announced an update on their ongoing clinical study.

Study Overview: Sab Biotherapeutics, Inc. is conducting a Phase 2b study titled ‘SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes.’ The study aims to evaluate the efficacy and safety of SAB-142 in delaying the progression of Type 1 Diabetes in patients with new onset Stage 3 Type 1 Diabetes. This research is significant as it targets a critical stage in diabetes management, potentially offering a new therapeutic approach.

Intervention/Treatment: The study tests two doses of SAB-142, a drug designed to slow the progression of Type 1 Diabetes. Participants will receive either a high dose, low dose, or a placebo, allowing researchers to assess the drug’s effectiveness and safety.

Study Design: This interventional study is randomized and features a parallel-arm model. It is double-blinded, meaning neither participants nor investigators know who receives the drug or placebo, ensuring unbiased results. The primary purpose is to evaluate the drug’s impact on diabetes progression.

Study Timeline: The study is not yet recruiting, with the first submission date recorded as September 8, 2025, and the last update on September 15, 2025. These dates indicate the study’s preparatory phase, with recruitment expected to commence soon.

Market Implications: This study’s progress could influence Sab Biotherapeutics’ stock performance, as successful results may enhance investor confidence and market positioning. The competitive landscape in diabetes treatment is robust, with numerous companies vying for breakthroughs, making this study’s outcome potentially impactful.

The study is ongoing, with further details available on the ClinicalTrials portal.